Celldex Therapeutics (NASDAQ:CLDX) Earns “Overweight” Rating from Cantor Fitzgerald

Celldex Therapeutics (NASDAQ:CLDX)‘s stock had its “overweight” rating reaffirmed by research analysts at Cantor Fitzgerald in a research report issued on Monday, Benzinga reports. They presently have a $67.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price would suggest a potential upside of 62.46% from the company’s previous close.

Several other equities research analysts have also commented on CLDX. Wolfe Research initiated coverage on shares of Celldex Therapeutics in a research report on Tuesday, June 11th. They issued an “outperform” rating and a $51.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a report on Monday, August 12th. Stifel Nicolaus initiated coverage on shares of Celldex Therapeutics in a research report on Tuesday, June 18th. They issued a “buy” rating and a $58.00 price target on the stock. Finally, Wells Fargo & Company lifted their price objective on Celldex Therapeutics from $35.00 to $37.00 and gave the stock an “equal weight” rating in a research report on Monday, August 12th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $63.83.

Celldex Therapeutics Price Performance

Shares of NASDAQ:CLDX opened at $41.24 on Monday. The firm has a market capitalization of $2.73 billion, a price-to-earnings ratio of -14.47 and a beta of 1.56. The business’s 50 day simple moving average is $38.35 and its 200-day simple moving average is $38.76. Celldex Therapeutics has a 12 month low of $22.11 and a 12 month high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.05. The firm had revenue of $2.50 million during the quarter, compared to analysts’ expectations of $1.13 million. Celldex Therapeutics had a negative return on equity of 23.66% and a negative net margin of 1,809.18%. On average, equities analysts anticipate that Celldex Therapeutics will post -2.5 earnings per share for the current year.

Institutional Investors Weigh In On Celldex Therapeutics

Several hedge funds have recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Celldex Therapeutics during the second quarter valued at approximately $76,000. Headlands Technologies LLC purchased a new position in shares of Celldex Therapeutics during the 1st quarter worth $147,000. CANADA LIFE ASSURANCE Co boosted its holdings in shares of Celldex Therapeutics by 26.4% during the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after purchasing an additional 955 shares during the last quarter. Ameritas Investment Partners Inc. grew its position in shares of Celldex Therapeutics by 34.3% in the first quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock valued at $260,000 after purchasing an additional 1,582 shares during the period. Finally, Aigen Investment Management LP acquired a new position in Celldex Therapeutics in the fourth quarter valued at $251,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.